Barclays lowered the firm’s price target on LivaNova (LIVN) to $55 from $56 and keeps an Equal Weight rating on the shares. The company reported a “robust beat” and its sales guidance was raised, the analyst tells investors in a research note. The firm says LivaNova’s Cardio and Epilepsy are on track for a solid 2025 performance.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN: